discovered by scRNA-seq combined with a prospective cohort study that d-MMR/MSI-H CRC patients who achieved pathological complete remission (pCR) post-PD-1 inhibitor treatment had a decrease in CCL2 fibroblasts, while CD20 B cells and HLA-DRA endothelial cells increased (66). Here, CCL2 is linked to colorectal carcinoma.